Results 71 to 80 of about 21,298 (206)

Impact of dual mTORC1/2 mTOR kinase inhibitor AZD8055 on acquired endocrine resistance in breast cancer in vitro [PDF]

, 2014
Introduction: Upregulation of PI3K/Akt/mTOR signalling in endocrine-resistant breast cancer (BC) has identified mTOR as an attractive target alongside anti-hormones to control resistance.
Carol M Dutkowski, Denise Barrow, Huw J Mottram, Iain R Hutcheson, Julia MW Gee, Nicola J Jordan, Robert I Nicholson, Sylvie M Guichard   +7 more
core   +1 more source

Cis‐regulatory and long noncoding RNA alterations in breast cancer – current insights, biomarker utility, and the critical need for functional validation

Molecular Oncology, Volume 20, Issue 4, Page 877-893, April 2026.
The noncoding region of the genome plays a key role in regulating gene expression, and mutations within these regions are capable of altering it. Researchers have identified multiple functional noncoding mutations associated with increased cancer risk in the genome of breast cancer patients.
Arnau Cuy Saqués, Aracele Martinez‐Mendez, John Crown, Alex Eustace   +3 more
wiley   +1 more source

Oral ethinylestradiol in castration resistent prostate cancer: 10 year experience [PDF]

, 2015
To describe our 10-year experience with the use of oral ethinylestradiol in the treatment of metastatic castration-resistant prostate cancer. METHODS: From February 2000 to April 2010, 116 patients with a metastatic castration-resistant prostate cancer
Aggarwal, Beer, Bonkhoff, Bono, Chadha, Corey, Di Silverio, Gasent Blesa, Izumi, Kitahara, Limonta, Montgomery, Shamash, Stein, Takezawa, Tannock, Wilkins   +16 more
core   +1 more source

Impact of Comorbidities on Clinical Outcomes and Quality of Life of Patients With Hormone Receptor‐Positive/Human Epidermal Growth Factor Receptor 2‐Negative (HR+/HER2−) Advanced Breast Cancer Treated With Palbociclib in the POLARIS Study

Cancer Medicine, Volume 15, Issue 4, April 2026.
ABSTRACT Background Comorbidities, common in patients with advanced breast cancer (ABC), may impact survival outcomes and health‐related quality of life (HRQoL). Here, we report subgroup analyses on the basis of comorbidities of patients from POLARIS (NCT03280303), a prospective, observational study of patients with hormone receptor‐positive/human ...
Debu Tripathy, Joanne L. Blum, Meghan S. Karuturi, Steven McCune, Sobha Kurian, Mehdi M. Moezi, Daniel M. Anderson, Yan Ji, Timothy J. Pluard, John Migas, Shailendra Lakhanpal, Erin Jepsen, Yao Wang, Monica Z. Montelongo, Zhe Zhang, Joseph C. Cappelleri, Eric Gauthier, Gabrielle B. Rocque   +17 more
wiley   +1 more source

Comparative efficacy of different targeted therapies plus fulvestrant for advanced breast cancer following progression on prior endocrine therapy: a network meta-analysis

Cancer Management and Research, 2018
Tingting Zhang,1,* Fubin Feng,2,* Wenge Zhao,3 Yan Yao,3 Jinhui Tian,4 Chao Zhou,2 Chuanxin Zang,1 Cun Liu,1 Xue Wang,5 Changgang Sun2,6 1College of Traditional Chinese Medicine, Shandong University of Traditional Chinese Medicine, Jinan, Shandong ...
Zhang T, Feng F, Zhao W, Yao Y, Tian J, Zhou C, Zang C, Liu C, Wang X, Sun C   +9 more
doaj  

Not So Fast: Cultivating miRs as Kinks in the Chain of the Cell Cycle. [PDF]

, 2017
In this issue of Cancer Cell, Hydbring and colleagues define a novel class of microRNAs (miRNAs), deemed cell-cycle-targeting miRNAs, that target several cyclins/CDKs, reduce tumor cell growth, and induce apoptosis.
Knudsen, Karen E., Schiewer, Matthew J.
core   +2 more sources

Male breast cancer [PDF]

, 2017
Male breast cancer (MBC) is a rare disease representing less than 1% of all breast cancers (BC) and less than 1% of cancers in men. Age at presentation is mostly in the late 60s.
A Bjørnerem, A Holleb, A Jemal, AC Antoniou, AM Shaaban, B D'Avanzo, Breast Cancer Linkage Consortium, C Gómez-Raposo, C Martinez-Bouzas, C Rudlowski, D Albo, D Ly, D Palli, DA Rigoni-Stern, DG Evans, DS Popovic, E Kreiter, EF Lewison, G Masci, G Ribeiro, GR Brown, I Ganly, I Sosnovskikh, I Zanna, IS Fentiman, IS Fentinam, J Boyd, J White, JD Fackenthal, JH Breasted, JL Gnerlich, JR Weiss, K Coard, K Syrjakoski, KA Johansen Taber, KD Crew, L France, L Ottini, L Ottini, LA Brinton, LA Brinton, LA Brinton, LA Brinton, LA Brinton, LA Korde, M Falchetti, M Golshan, MA Adank, MB Cook, ME Meijer-van Gelder, MM Munoz de Toro, MT Vietri, N Orr, N Rahman, O Gentilini, P Karamanakos, RM Ferzoco, S Paik, S Peng, S Shak, S Thorlacious, SH Giordano, SH Giordano, SH Giordano, T Grenader, V Silvestri, V Silvestri, V Speirs, WF Anderson, WF Anderson, Y Ge, ZI Mitri   +71 more
core   +1 more source

Annual Banned‐Substance Review 18th Edition—Analytical Approaches in Human Sports Drug Testing 2024/2025

Drug Testing and Analysis, Volume 18, Issue 4, Page 458-482, April 2026.
New insights into drug metabolism, distribution, elimination, and detection assays for drugs and methods of sports doping published between 2024 and 2025 are critically reviewed and evaluated in context with the Prohibited List 2025 as established by the World Anti‐Doping Agency.
Mario Thevis, Tiia Kuuranne, Hans Geyer
wiley   +1 more source

An Experimental Analysis of the Molecular Effects of Trastuzumab (Herceptin) and Fulvestrant (Falsodex), as Single Agents or in Combination, on Human HR+/HER2+ Breast Cancer Cell Lines and Mouse Tumor Xenografts.

PLoS ONE, 2017
PurposeTo investigate the effects of trastuzumab (herceptin) and fulvestrant (falsodex) either in combination or alone, on downstream cell signaling pathways in lab-cultured human HR+/HER2+ breast cancer cell lines ZR-75-1 and BT-474, as well as on ...
Qing Chen, Ziyi Weng, Yunshu Lu, Yijun Jia, Longlong Ding, Fang Bai, Meixin Ge, Qing Lin, Kejin Wu   +8 more
doaj   +1 more source

The Effects and Mechanisms of Pomegranate on Regulating Lipid Metabolism

Food Science &Nutrition, Volume 14, Issue 4, April 2026.
This study established a high‐fat diet‐induced hyperlipidemia rat model to investigate the lipid‐lowering effects of pomegranate. Pomegranate intervention significantly reduced serum total cholesterol (TC), triglyceride (TG), and low‐density lipoprotein cholesterol (LDL‐C) levels, while alleviating hepatic steatosis by decreasing liver weight and fat ...
Hao Wang, Jingtao Liu, Xin Dong, Tiantian Shi, Xuena Zhang, Yide He, Shaonan Hu, Yuewu Wang, Jian Zheng, Peifeng Xue   +9 more
wiley   +1 more source